Portfolio company
EsoBiotec
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
The company develops off-the-shelf in vivo cell therapies to treat cancer and autoimmune diseases for patients and pharmaceutical partners.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Azalea Therapeutics
The company develops in vivo genome editing therapies to engineer T cells directly inside the body for patients with cancer and autoimmune diseases.
T-Therapeutics
The company develops T cell receptor therapeutics and bispecific engagers for patients with cancer and autoimmune diseases.
EpiBiologics
This company develops bispecific antibodies to degrade extracellular proteins for patients with cancer and autoimmune disorders.
EdiTy Therapeutics
This company develops immune cell delivery platforms to transport therapeutic proteins into diseased cells for patients with cancer and genetic disorders.
Modulari-T Biosciences
This company develops modular immune receptors and delivery vehicles to create cell and gene therapies for patients with cancer and autoimmune diseases.
Egle Therapeutics
This biotechnology company develops precision medicines that modulate regulatory T cells to treat patients with autoimmune diseases and cancer.
Captain T Cell
The company develops cell therapies for cancer patients to treat solid tumours.
Outpace Bio
This biotechnology company develops custom protein-designed cell therapies to treat solid tumours and autoimmune diseases for patients and pharmaceutical partners.